Taiho Pharma said that Abraxane features improved efficacy and safety as well as easier administration compared to solvent-based paclitaxel.
Originally, Abraxane was developed by Abraxis BioScience as a novel paclitaxel formulation for breast cancer treatment.
The US Food and Drug Administration has granted approval for the drug in January 2005.